Rise of ADCs: Expanding Applications and the Road to Commercialisation

The development of antibody-drug conjugates (ADCs) has advanced significantly in the biopharmaceutical sector; in the last five years, eight of the 14 ADCs that are currently approved have obtained regulatory approval. The quantity of pre-clinical to commercial ADC compounds in the innovative modality pipeline increased by more than 25 per cent year over year, according to a market trend. ADCs have the potential to transform targeted medicine and give patients everywhere new hope with further development and wise funding.

- Benjamin Hein

Over the past decade, interest in Antibody-Drug Conjugates (ADCs) has surged, driven by their promise for patients, advancements in research, clinical adoption, and market expansion. It is estimated that the global market for ADCs could reach upwards of more than €24 billion by 2030, according to a Grand View Research report.

While initially focused on oncology, ADC development is now extending into non-cancerous diseases, such as cardiovascular and inflammatory diseases, marking a significant milestone for the biopharmaceutical industry and an opportunity for further growth of the modality. A year-over-year market trend reveals that the number of pre-clinical to commercial ADC molecules in the novel modality pipeline grew more than 25 per cent.

Because of their unique structure and mechanism of action, ADCs require special regulatory considerations when compared to biologics and small molecule drugs. Still, developers are finding success amidst this complex regulatory landscape, underscoring the growing potential of these bioconjugates. A significant portion of ADC projects are outsourced to contract development and manufacturing organisations (CDMOs) and with the continued expansion of pipelines, this trend is likely to continue.

Growing Impact of ADCs

ADCs represent a transformative approach to oncology, enabling targeted therapies that minimise damage to healthy tissues. They consist of a monoclonal antibody, a chemotherapy drug (payload), and a chemical linker that ensures precise drug release within target cells. This approach enhances efficacy while minimising off-target toxicity, making ADCs a more precise alternative to traditional chemotherapy. As the market for this novel modality grows and the medical community adopts them as first-line treatments, it may mean that fewer patients need invasive treatments like chemotherapy and radiation that cause significant side effects.